20
total announcements
506414.BO · 15 min delayed
Fermenta Biotech Ltd
Fermenta Biotech Ltd has announced an investor meeting on September 3, 2026, in Mumbai, where company officials will discuss press releases and investor presentations available on the company's website and stock exchanges.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has published a notice for a special window for transfer and dematerialization of physical securities in Business Standard and Sakal newspapers on August 26, 2026.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has announced an investor meeting to be held on August 21, 2026, where the company officials will interact with investors. The meeting will be held in Mumbai and will discuss the company's press releases and investor presentations available on its website and stock exchange websites.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has received a letter from CARE Ratings Ltd informing a revision in its credit rating. CARE's Rating Committee has upgraded the ratings for the company's long-term and short-term bank facilities.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has published its unaudited financial results for the quarter ended June 30, 2026, in newspapers as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Fermenta Biotech Ltd
Fermenta Biotech Ltd held its 74th Annual General Meeting on August 11, 2026, through Video Conferencing/Other Audio Visual Means. The meeting commenced at 3:00 p.m. (IST) and concluded at 5:12 p.m. (IST). The results of remote e-voting (including ballot forms) and electronic voting on all the resolutions set out in the notice of the 74th Annual General Meeting were declared. All resolutions were duly approved by the members with requisite majority.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has announced the voting results of its 74th Annual General Meeting, where all resolutions were passed with the requisite majority. The company has declared a dividend of Rs. 3.75 per equity share and appointed a new director in place of Ms. Rajeshwari Datla. The resolutions related to the appointment and continuation of Ms. Datla as a Non-Executive Director were also approved.
Fermenta Biotech Ltd
Fermenta Biotech Ltd's 74th Annual General Meeting (AGM) has approved the appointment of Ms. Rajeshwari Datla as a Non-Executive Director, payment of a 75% dividend of Rs. 3.75 per equity share, and commission to Non-Executive Directors. The meeting also approved material related party transactions with Fermenta USA LLC, a step-down subsidiary.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has announced its 74th Annual General Meeting presentation, highlighting its operating momentum, renewed strategic conviction, and capital commitment. The company has achieved a record topline of ₹548 crore, up 14% from ₹481 crore in FY25, and has granted a patent for its plant-source Vitamin D3 process. It has also secured EDQM CEP for D3 100 SD and approved ₹110 crore of new Dahej capacity.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has announced its Q1FY27 earnings presentation, with revenue near flat sequentially at INR 126.2 crore, driven by a 24% QoQ increase in human nutrition revenue to INR 76.5 crore. The company's largest business segment, human nutrition, contributed 61% to the revenue, while animal nutrition remained a soft spot with volumes down 52% QoQ and 20% YoY. Fermenta's EBITDA declined 37% YoY to INR 9.5 crore, and profit after tax was down 56% YoY to INR 11.6 crore.
Fermenta Biotech Ltd
Fermenta Biotech Ltd announced unaudited financial results for Q1FY27, with consolidated revenue of INR 126.2 crore, down 13% YoY and flat QoQ. EBITDA was INR 22.4 crore, down 39% YoY and 11% QoQ. Profit after tax was INR 9.5 crore, down 56% YoY and 49% QoQ.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with the Board of Directors approving the results at a meeting held on August 11, 2026. The company has enclosed the Limited Review Reports on the financial results issued by M/s. SRBC & Co. LLP, Chartered Accountants, with an unmodified opinion.
Fermenta Biotech Ltd
Fermenta Biotech Ltd's board meeting on August 11, 2026, approved unaudited financial results for the quarter ended June 30, 2026. The company received an unmodified opinion from statutory auditors SRBC & Co. LLP.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has announced an investor meeting on August 17, 2026, in Mumbai, where the company officials will discuss press releases and investor presentations available on the company's website and BSE's website.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 11/08/2026 to consider and approve unaudited financial results for the quarter ended June 30, 2026.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has listed its shares on the National Stock Exchange (NSE) under the symbol FERMENTA and ISIN INE225B01021, expanding its capital-market presence and increasing accessibility to a wider community.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has been listed on the National Stock Exchange of India Limited (NSE) with effect from August 04, 2026. The company's existing 2,94,30,987 equity shares have been admitted to dealings on the NSE.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has announced an investor meeting on July 29, 2026, in Mumbai. The meeting will be held one-to-one with investors, and the company will discuss press releases and investor presentations available on its website. No unpublished price-sensitive information will be discussed during the interaction.
Fermenta Biotech Ltd
Fermenta Biotech Ltd has published a notice for its 74th Annual General Meeting (AGM) in newspapers as per SEBI regulations.
Fermenta Biotech Ltd
Fermenta Biotech Ltd announced an upcoming one-to-one physical meeting with investors in Mumbai on June 26, 2026. During the interaction, company officials will discuss the audited financial results for the year ended March 31, 2026, utilizing the previously uploaded press release and investor presentation. The company explicitly stated that no unpublished price sensitive information (UPSI) will be disclosed during this meeting.